About: Acute antihyperglycemic mechanisms of metformin in NIDDM. Evidence for suppression of lipid oxidation and hepatic glucose production

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Acute antihyperglycemic mechanisms of metformin in NIDDM. Evidence for suppression of lipid oxidation and hepatic glucose production Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 July 1994

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в липні 1994 (uk) im Juli 1994 veröffentlichter wissenschaftlicher Artikel (de) artículu científicu espublizáu en xunetu de 1994 (ast) scientific article published on 01 July 1994 (en)
publication date	wds:Q72020678-EF8C8BFD-3DC2-4F95-A1BD-15E996F84485
publication date	1994-07-01 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q72020678-3A1DAF6F-87EE-4CB2-A355-7768C3CE8700
language of work or name	English
author name string	wds:Q72020678-016C6F7E-67B0-4ABC-B180-72D85BD6C254 wds:Q72020678-2C6507FE-ABD2-4981-A69C-DDCF1EBCF827 wds:Q72020678-4C01AAD1-14BC-45A8-A586-B8182AB44249 wds:Q72020678-4E10B64F-91DC-4649-ABB8-31AEC3CFC42D wds:Q72020678-7DD8A20B-CDC9-4D7A-8D76-FBC8F02DC2F2 wds:Q72020678-7E4A717C-B823-4CF7-829F-EF58F7FFD3F7 wds:Q72020678-B6B6D61B-0513-49A6-BE52-449E515EFAB5 wds:Q72020678-CE1E9C32-E825-4F6E-B7A6-FF1336183417 wds:Q72020678-F4905422-1A3A-454C-A8DF-08B8B0E4DA96
author name string	E Volpi G Perriello P Brunetti G B Bolli A Santucci F Santeusanio C Santucci M M Ventura P Misericordia
rdfs:label	Acute antihyperglycemic mechanisms of metformin in NIDDM. Evidence for suppression of lipid oxidation and hepatic glucose production (en) Acute antihyperglycemic mechanisms of metformin in NIDDM. Evidence for suppression of lipid oxidation and hepatic glucose production (nl)
skos:prefLabel	Acute antihyperglycemic mechanisms of metformin in NIDDM. Evidence for suppression of lipid oxidation and hepatic glucose production (en) Acute antihyperglycemic mechanisms of metformin in NIDDM. Evidence for suppression of lipid oxidation and hepatic glucose production (nl)
name	Acute antihyperglycemic mechanisms of metformin in NIDDM. Evidence for suppression of lipid oxidation and hepatic glucose production (en) Acute antihyperglycemic mechanisms of metformin in NIDDM. Evidence for suppression of lipid oxidation and hepatic glucose production (nl)
author	wds:Q72020678-6C0D072E-B4F8-4175-988F-10CD0FC9B541
author	Eleuterio Ferrannini
title	wds:Q72020678-22F766FF-0A85-453D-A39E-2BD9DE0F1448
title	Acute antihyperglycemic mechanisms of metformin in NIDDM. Evidence for suppression of lipid oxidation and hepatic glucose production (en)
page(s)	wds:Q72020678-A10DF420-3FE5-4984-9C90-D0B196DFCEE4
page(s)	920-928
instance of	wds:Q72020678-36A53BD1-EB27-43F0-B23C-E27AA646E6EA
instance of	scholarly article
main subject	wds:Q72020678-08864C1E-CC15-4371-B07E-645780AE7518
main subject	metformin
PubMed ID	wds:Q72020678-641A5F8A-5D97-4448-8BEB-8AC48695CA5F
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/8013758
PubMed ID	8013758
published in	wds:Q72020678-05F237C1-9C81-4B53-AC67-7C51B11A82B7
published in	Diabetes
issue	wds:Q72020678-2B867869-86BE-4252-8F77-0403503E1D96
volume	wds:Q72020678-6C5CF51D-2E55-4CEE-AF55-963741CC5891
issue	7
volume	43
number of pages	wds:Q72020678-3ADB55D6-322F-40BC-B367-F02E667649B4
number of pages	9 (xsd:decimal)
DOI	wds:Q72020678-09797A5E-C13E-4692-BDEB-991CE02EEFF9
DOI	http://dx.doi.org/10.2337/DIAB.43.7.920
DOI	10.2337/DIAB.43.7.920
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q72020678
is cites work of	Mechanism by which metformin reduces glucose production in type 2 diabetes Metformin for women who are obese during pregnancy for improving maternal and infant outcomes Metformin for women who are overweight or obese during pregnancy for improving maternal and infant outcomes Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus Metformin Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. Effects of gliclazide versus metformin on the clinical profile and lipid peroxidation markers in type 2 diabetes Metformin reverses fatty liver disease in obese, leptin-deficient mice Metformin and phenformin activate AMP-activated protein kinase in the heart by increasing cytosolic AMP concentration The antihyperglycaemic effect of metformin: therapeutic and cellular mechanisms Metformin and free fatty acid metabolism Effect of metformin on fatty acid and glucose metabolism in freshly isolated hepatocytes and on specific gene expression in cultured hepatocytes Oxidative stress, insulin resistance, dyslipidemia and type 2 diabetes mellitus Metformin or gliclazide, rather than glibenclamide, attenuate progression of carotid intima-media thickness in subjects with type 2 diabetes Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic review An overview of metformin in the treatment of type 2 diabetes mellitus Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain Molecular mechanism of action of metformin: old or new insights? Metformin ameliorates hepatic steatosis and inflammation without altering adipose phenotype in diet-induced obesity Effects of metformin on glucose metabolism of perfused rat livers Androgen receptor antagonism and an insulin sensitizer block the advancement of vaginal opening by high-fat diet in mice Dietary interventions to extend life span and health span based on calorie restriction Survival after metformin-associated lactic acidosis in peritoneal dialysis--dependent renal failure Effects of metformin in obese patients with impaired glucose tolerance Cellular mechanisms of insulin resistance in humans Metformin: new understandings, new uses A risk-benefit assessment of metformin in type 2 diabetes mellitus Therapeutic trials in nonalcoholic steatohepatitis: insulin sensitizers and related methodological issues Biguanides and thiazolidinediones inhibit stimulated lipolysis in human adipocytes through activation of AMP-activated protein kinase Is glycation of low density lipoproteins in patients with Type 2 diabetes mellitus a LDL pre-oxidative condition? Prevention of complications in non-insulin-dependent diabetes mellitus (NIDDM). Drug therapy of non-insulin-dependent diabetes mellitus in the elderly Metformin improves atypical protein kinase C activation by insulin and phosphatidylinositol-3,4,5-(PO4)3 in muscle of diabetic subjects Metformin treatment may increase omentin-1 levels in women with polycystic ovary syndrome Treatment update: thiazolidinediones in combination with metformin for the treatment of type 2 diabetes Metformin Antagonizes Cancer Cell Proliferation by Suppressing Mitochondrial-Dependent Biosynthesis Two weeks of metformin treatment induces AMPK-dependent enhancement of insulin-stimulated glucose uptake in mouse soleus muscle. The effects of metformin and diet on plasma testosterone and leptin levels in obese men. Metformin Inhibits Isoproterenol-induced Cardiac Hypertrophy in Mice

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 171 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software